Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ASP2802 + MA-20** is an experimental combination therapy consisting of ASP2802, a CAR-T cell therapy targeting CD20-positive B cells, and MA-20, an adjunctive protein intended to enhance the in vivo function or persistence of the CAR-T cells. ASP2802 is designed to recognize and bind to CD20, a surface antigen found on malignant B cells, facilitating their destruction by the engineered T cells. MA-20 is co-administered to improve the efficacy of the cellular therapy, although its precise mechanism of action is not fully detailed in the available sources[1][2][4]. The combination has been tested primarily in patients with CD20-positive B-cell lymphomas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ASP2802 + MA-20.